3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(1-methylcyclobutyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine
C18H19FN8O — CID 142608576
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(1-methylcyclobutyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine
3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(1-methylcyclobutyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine (PubChem CID 142608576) has the molecular formula C18H19FN8O and a molecular weight of 382.40 g/mol. Its IUPAC name is 3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(1-methylcyclobutyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine.
Molecular Properties
| Compound Name | 3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(1-methylcyclobutyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine |
|---|---|
| PubChem CID | 142608576 |
| Molecular Formula | C18H19FN8O |
| Molecular Weight | 382.40 g/mol |
| Exact Mass | 382.17 |
| IUPAC Name | 3-(2-amino-4-fluoro-1,3-benzoxazol-5-yl)-1-[(1-methylcyclobutyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-diamine |
| SMILES | CC1(Cn2nc(-c3ccc4oc(N)nc4c3F)c3c(N)nc(N)nc32)CCC1 |
| InChI | InChI=1S/C18H19FN8O/c1-18(5-2-6-18)7-27-15-10(14(20)24-16(21)25-15)12(26-27)8-3-4-9-13(11(8)19)23-17(22)28-9/h3-4H,2,5-7H2,1H3,(H2,22,23)(H4,20,21,24,25) |
| InChIKey | JUVAOVBSTMBYPN-UHFFFAOYSA-N |
| XLogP | 2.71 |
| TPSA | 147.69 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 382.40 |
| LogP ≤ 5 | 2.71 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 142608576 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.